Market News How it works Learn FAQ
| GPUS 0.1689 34.05% | XXII 0.1977 -8.34% | SHFS 0.1324 -61.39% | NVD 4.19 0.96% | LUCD 0.411 25.42% | SPCX 147.49 1.89% | T 20.93 -7.96% | SOXL 83.56 1.77% | NU 15.16 2.92% | NOK 8.14 3.30% | EWZ 42.59 1.77% | NVDA 210.96 -0.59% | RIME 0.106 -12.90% | INTC 86.96 1.72% | TSLG 4.87 -1.62% | AAL 12.11 -3.89% | BBD 4.07 3.04% | STLA 4.06 -4.81% | SOXS 52.46 -1.85% | RWM 14.55 0.34% | HYG 77.05 -0.06% | MYND 0.24 47.42% | BITO 10.83 -0.28% | SPDN 8.54 0.47% | YFOR 0.2236 -1.58% | RBNE 0.19 -2.56% | TQQQ 66.29 -0.20% | VZ 44.66 -1.19% | TSLL 9.76 -1.21% | SPTI 27.63 -0.11% | YMAT 2.05 6.77% | CRWV 54.235 -2.46% | INFY 12.35 -6.58% | RIG 6.41 5.43% | F 11.6 -2.85% | SQQQ 39.68 0.20% | AIOK 12.02 182.82% | ONDS 6.2 2.99% | AAPL 347.725 -0.14% | LABT 0.31 -36.67% | CDE 13.45 -3.10% | PCG 12.63 -2.70% | GRAB 2.79 -2.11% | SOFI 14.615 -1.05% | XLE 69.33 2.60% | IREN 24.905 -2.37% | QID 14.55 0.14% | RKT 11.73 -0.09% | WULF 11.32 0.00% | BE 193.3 -11.24%
CPCumberland Pharmaceuticals Inc. logo

Cumberland Pharmaceuticals Inc. (CPIX)

NASDAQ Global Select · Currency in USD
$8.49 ▲ +0.01 (+0.12%)
At close: Oct 23, 4:00 PM ET. Market closed.
$7.50 ▼ -0.99 (-11.66%)
After hours: Oct 23, 7:42 PM ET

Summary

Previous Close
$8.48
Open
$8.46
Day's Range
$8.33 – $8.75
52 Week Range
$1.85 – $9.28
Volume
26,818
Avg. Volume
78,577
Market Cap
$127.21M
Beta (5Y Monthly)
0.10
PE Ratio (TTM)
--
EPS (TTM)
-$0.71
Earnings Date
Nov 3, 2026
Forward Dividend & Yield
--
Ex-Dividend Date
Aug 3, 2026
1y Target Est
--

Profile: Cumberland Pharmaceuticals Inc.

Sector
Healthcare
Industry
Drug Manufacturers - Specialty & Generic
Full-time employees
88
CEO
A. J. Kazimi

Cumberland Pharmaceuticals Inc. functions as a specialized pharmaceutical enterprise, primarily involved in the procurement, advancement, and commercialization of prescription medications. Its strategic focus areas include acute hospital care, gastroenterology, rheumatology, and oncology, with operations spanning both the United States and global markets. The company's existing product line includes: Acetadote: an injectable solution for treating acetaminophen poisoning.

Earnings

Next report: Tue, Nov 3, 2026
EPS estimate -$0.13 · Revenue est. $8.50M
DateEst.Actual
Aug 4, 2026-$0.13-$0.20Miss
May 5, 2026-$0.13-$0.13Beat
Mar 3, 2026-$0.13-$0.01Beat
Nov 4, 2025-$0.13-$0.06Beat
Aug 5, 2025–$0.02
May 6, 2025-$0.01$0.16Beat

Analyst view

Rating: Buy
Buy 60% · Hold 40% · Sell 0%

Get free alerts on CPIX and big market moves

Free special alerts by text & email on new investment opportunities, buyouts and the stocks moving most, in plain English.
Get free stock alerts →
Data: Financial Modeling Prep. For information only, not investment advice.